Welcome to our dedicated page for DiaMedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
Dialectic Life Sciences SPV LLC, related Dialectic entities, and John Fichthorn updated their ownership report on DiaMedica Therapeutics Inc. common shares. The Dialectic entities now report beneficial ownership of 0 shares, or 0.0% of the class. Fichthorn individually reports beneficial ownership of 153,983 voting common shares, representing 0.3% of the outstanding class, with sole voting and dispositive power over this amount.
DiaMedica Therapeutics Inc. received an amended ownership report showing that Swedish investor Trill AB and its board member Jan Stahlberg beneficially own 8,825,742 common shares, representing 16.9% of the company.
All of these shares are reported with shared voting and shared dispositive power; neither Trill AB nor Stahlberg reports sole power to vote or dispose of any shares. The percentage is based on 52,077,439 DiaMedica common shares outstanding as of November 10, 2025, as disclosed in a recent quarterly report. The filing also certifies that the position is held on a passive basis, not for the purpose of changing or influencing control of DiaMedica.
DiaMedica Therapeutics Inc. director Semba Charles Pauling reported an equity-based compensation grant. On January 2, 2026, he acquired 3,355 shares of common stock at $8.42 per share, bringing his directly held stake to 47,963 shares.
The footnote explains that these shares are issuable upon settlement of restricted stock units granted under the company’s Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees totaling $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026, meaning the director earns the related shares over the course of the year as service-based conditions are met.
DiaMedica Therapeutics Inc. reported an update on its DM199 preeclampsia program following a pre-IND meeting with the U.S. Food and Drug Administration. The FDA requested one additional non-clinical 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model before proceeding with the planned study of DM199 in preeclampsia. Preparations for this new rabbit study have begun and results are expected to be available by the second quarter of 2026.
The company reiterates forward-looking statements about the potential clinical benefits of DM199 for preeclampsia and acute ischemic stroke, and notes that outcomes depend on future non-clinical and clinical results, regulatory feedback, funding, and operational factors such as site activation and enrollment in trials.
DiaMedica Therapeutics Inc. (DMAC) director reports stock option exercise. A company director exercised a stock option to acquire 12,000 common shares of DiaMedica on 11/21/2025 at an exercise price of $2.20 per share, with the price shown after converting the original CAD$ exercise price to US$ on the transaction date. Following this transaction, the director directly owns 87,854 common shares of DiaMedica. The derivative position reported was a stock option (right to buy) for 12,000 shares that was fully vested and, after the exercise, the number of derivative securities beneficially owned is reported as 0.
DiaMedica Therapeutics Inc. (DMAC) filed a Form S-8 registering 1,000,000 common shares for issuance under its 2021 Employment Inducement Incentive Plan.
The Board amended the plan on July 31, 2025 to reserve an additional 1,000,000 shares for equity awards to individuals who were not previously employees or directors, as an inducement to employment under Nasdaq Listing Rule 5635(c)(4). The plan allows stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, and other stock-based awards.
DiaMedica Therapeutics (DMAC) filed its Q3 2025 10-Q, highlighting a clinical-stage focus on DM199 for preeclampsia (PE) and acute ischemic stroke (AIS). For the nine months ended September 30, 2025, the company reported a net loss of $24.0 million and used $21.3 million in operating cash. As of September 30, 2025, cash, cash equivalents and marketable securities were $55.3 million, with working capital of $51.0 million.
R&D expenses were $6.4 million in Q3 (up from $5.0 million a year ago) and G&A was $2.6 million (up from $1.9 million), reflecting ongoing ReMEDy2 trial activities and PE program work. The company completed a July 2025 private placement of 8,606,425 shares at $3.50 for $30.1 million gross (~$30.0 million net) and sold 223,472 shares via its ATM for $1.6 million gross; up to $100 million may be sold under the ATM, with $98.4 million remaining as of quarter end.
In PE, interim Phase 2 results (N=28) showed DM199 appeared safe with blood pressure reductions. In AIS, ReMEDy2 site activations and enrollment remain slower than expected; interim analysis is estimated in the second half of 2026, and UK approval to conduct the study was received on August 28, 2025.
DiaMedica Therapeutics (DMAC) reported a Form 4 for its Chief Marketing Officer showing a grant of stock options to purchase 450,000 shares at an exercise price of $4.58 per share on 08/11/2025. The options expire on 08/10/2035 and were reported as directly owned following the transaction.
The filing states a time-based vesting schedule: 112,500 options vest on the one-year anniversary of the grant date, and the remaining 337,500 vest in twelve equal quarterly installments starting three months after that one-year mark, conditioned on continued service.
DiaMedica Therapeutics Inc. (DMAC) filed a Form 3 initial statement of beneficial ownership for its Chief Marketing Officer. The filing states that no securities are beneficially owned. The event date was 08/11/2025.
The form was signed by attorney-in-fact Joshua L. Colburn pursuant to a Power of Attorney. This is a routine administrative disclosure and does not report any transactions.
Insider purchases increased a single beneficial stake to 7,764,465 shares of DiaMedica Therapeutics (DMAC). From August 13 to August 27, 2025, a series of open-market purchases totaling multiple transactions were reported, with individual purchase sizes ranging from 8,233 to 338,265 shares at per-share prices between $5.8573 and $6.00. The shares are owned directly by Trill AB and indirectly by Jan Stahlberg, a company director and 10% owner, who "has the sole power to vote and dispose" of the shares. The Form 4 shows continued accumulation over a two-week period via multiple purchases, and the filing is signed by Jan Stahlberg and by him as Board Member of Trill AB.